Crescent Biopharma
CBIO
58 hedge funds and large institutions have $82.8M invested in Crescent Biopharma in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 6 closing their positions.
454% more call options, than puts
Call options by funds: $382K | Put options by funds: $69K
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
59% more capital invested
Capital invested by funds: $52.1M → $82.8M (+$30.8M)
18% more funds holding
Funds holding: 49 → 58 (+9)
0.01% more ownership
Funds ownership: 0.54% → 0.55% (+0.01%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$194K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$173K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$167K |
| 4 |
AO
Advisor OS
Chicago,
Illinois
|
+$157K |
| 5 |
MA
MJP Associates
Farmington,
Connecticut
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$471K |
| 2 |
Renaissance Technologies
New York
|
-$119K |
| 3 |
Two Sigma Investments
New York
|
-$84.7K |
| 4 |
Two Sigma Advisers
New York
|
-$83.3K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$66.8K |
CBIO Hedge Fund Activity: Q4 2023 in Review
58 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2023, worth a combined $82.8M — up 59% from $52.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CBIO positions and 6 closed out — a net gain of 9 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $194K. The largest seller was Acadian Asset Management, cutting an estimated $471K.
- 58 institutional investors held Crescent Biopharma (CBIO) as of Q4 2023, up from 49 in Q3 2023.
- Funds reported $82.8M of Crescent Biopharma stock for Q4 2023, up 59% quarter-over-quarter.
- 15 funds opened new Crescent Biopharma positions in Q4 2023 and 6 closed out, a net change of +9 holders.
- The largest Crescent Biopharma buyer in Q4 2023 was Goldman Sachs, an estimated $194K added.
- The largest Crescent Biopharma seller in Q4 2023 was Acadian Asset Management, an estimated $471K sold.
Based on aggregated 13F filings for Q4 2023.